BidziÅ„ski Mariusz

List of Publications by Year
in descending order

54	3,814	304743 22	168389 53
papers	citations	h-index	g-index

55	55	55	7281
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
3	Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 3107-3114.	1.6	371
4	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2016, 17, 78-89.	10.7	205
5	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. International Journal of Gynecological Cancer, 2017, 27, 832-837.	2.5	149
6	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOâ€"The MIMOSA Study. Journal of Clinical Oncology, 2013, 31, 1554-1561.	1.6	126
7	Increased cancer risk of heterozygotes withNBS1 germline mutations in poland. International Journal of Cancer, 2004, 111, 67-71.	5.1	118
8	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. Journal of Clinical Oncology, 2012, 30, 3841-3847.	1.6	110
9	Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology, 2008, 109, 174-181.	1.4	104
10	Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecologic Oncology, 2020, 156, 575-582.	1.4	53
11	PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Human Pathology, 2011, 42, 1710-1719.	2.0	51
12	Early Cervical Cancer Managed by Laparoscopy and Conventional Surgery. International Journal of Gynecological Cancer, 2009, 19, 1390-1395.	2.5	47
13	The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma. Gynecologic Oncology, 2010, 116, 473-477.	1.4	45
14	Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. Gynecologic Oncology, 2018, 150, 552-561.	1.4	45
15	Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression. EBioMedicine, 2019, 47, 170-183.	6.1	41
16	The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumor Biology, 2016, 37, 1271-1278.	1.8	37
17	Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. Journal of Cancer Research and Clinical Oncology, 2007, 133, 361-371.	2.5	32
18	The quality of life of women treated for cervical cancer. European Journal of Oncology Nursing, 2012, 16, 59-63.	2.1	28

#	Article	IF	Citations
19	microRNAs in uterine sarcomas and mixed epithelialâ€“mesenchymal uterine tumors: a preliminary report. Tumor Biology, 2013, 34, 2153-2160.	1.8	28
20	Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma. Tumor Biology, 2017, 39, 101042831771714.	1.8	27
21	TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study. BMC Cancer, 2008, 8, 27.	2.6	26
22	Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. International Journal of Cancer, 2005, 116, 957-962.	5.1	24
23	Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients. PLoS ONE, 2017, 12, e0184576.	2.5	23
24	Uterine tumors resembling ovarian sex cord tumors, a clinicopathologic study of six cases. Annals of Diagnostic Pathology, 2014, 18, 329-332.	1.3	21
25	High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genetics, 2012, 205, 94-100.	0.4	19
26	Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World Journal of Surgical Oncology, 2016, 14, 58.	1.9	19
27	Laparoscopic Ligature of the Hypogastric Artery in the Case of Bleeding in Advanced Cervical Cancer. Gynecologic Oncology, 2002, 84, 344-348.	1.4	18
28	Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients. International Journal of Gynecological Cancer, 2010, 20, 588-592.	2.5	18
29	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. Current Gynecologic Oncology, 2017, 15, 5-23.	0.1	16
30	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. JCI Insight, 2017, 2, .	5.0	15
31	The Frequency of Human Papillomavirus Infection in Polish Patients With Vulvar Squamous Cell Carcinoma. International Journal of Gynecological Cancer, 2010, 20, 434-437.	2.5	13
32	The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 263, 139-147.	1.1	12
33	Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes. BMC Cancer, 2012, 12, 223.	2.6	11
34	Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors. Clinical Biochemistry, 2012, 45, 368-371.	1.9	10
35	Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. Archives of Gynecology and Obstetrics, 2012, 286, 1513-1519.	1.7	9
36	CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. Journal of Clinical Pathology, 2022, 75, 324-332.	2.0	9

#	Article	IF	Citations
37	Recommendations of the Polish Gynecological Oncology Society for the diagnosis andtreatment of endometrial cancer. Current Gynecologic Oncology, 2017, 15, 34-44.	0.1	8
38	Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients. Oncology Letters, 2011, 2, 537-541.	1.8	7
39	Lack of microsatellite instability in squamous cell vulvar carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 391-394.	2.8	7
40	CHFR gene is neither mutated nor hypermethylated in ovarian cancer. Cancer Detection and Prevention, 2007, 31, 257-261.	2.1	6
41	The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. Oncology Letters, 2012, 4, 551-555.	1.8	6
42	Laparoscopic sentinel lymph node mapping after cervical injection of indocyanine green for endometrial cancer â€“ preliminary report. Wideochirurgia I Inne Techniki Maloinwazyjne, 2015, 3, 406-412.	0.7	6
43	Recommendations of the Polish Gynecological Oncology Society for the diagnosis andtreatment of cervical cancer. Current Gynecologic Oncology, 2017, 15, 24-33.	0.1	6
44	Comparison of cytogenetic changes between primary and relapsed patients with borderline tumors of the ovary. Cancer Genetics and Cytogenetics, 2009, 195, 157-163.	1.0	2
45	Contemporary principles of diagnostic and therapeutic management in cervical and ovarian neuroendocrine tumors. Ginekologia Polska, 2021, 92, 312-317.	0.7	2
46	Recommendations of Polish Gynecological Oncology Society concerning epithelial tumors of the ovary: ovarian cancer and borderline tumors. Current Gynecologic Oncology, 2013, 11, 9-23.	0.1	2
47	Contraception for cancer survivors. Ginekologia Polska, 2013, 84, 955-8.	0.7	2
48	The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland. Ginekologia Polska, 2017, 88, 296-301.	0.7	2
49	Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIBâ€“IIIB cervical cancer treated with radiochemotherapy. Gynecologic Oncology, 2007, 104, 24-31.	1.4	1
50	An evaluation of the construction of the device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer. Wspolczesna Onkologia, 2019, 23, 171-177.	1.4	1
51	Prognosis of the patients suffered from uterine carcinosarcoma from rural and urban areas. Ginekologia Polska, 2021, , .	0.7	1
52	Recommendations of the Polish Gynecological Oncology Society for the diagnosis andtreatment of vulvar cancer. Current Gynecologic Oncology, 2017, 15, 45-53.	0.1	1
53	Gene therapy of locally advanced vulvar cancer with psFLT construct. Wspolczesna Onkologia, 2010, 1, 11-14.	1.4	0
54	Trabectedin for the treatment of ovarian cancer. Current Gynecologic Oncology, 2017, 15, 218-223.	0.1	0